HUGE | FSD Pharma Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0870 - 0.1042
52 Week Range	0.0870 - 109.19
Beta	0.63
Implied Volatility	501.72%
IV Rank	7.36%
Day's Volume	22,015,006
Average Volume	196,163
Shares Outstanding	741,612
Market Cap	66,671
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2018-06-08

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-16.25
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	17
Country	Canada
Website	HUGE

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

HUGE's peers: BFRI, RMTI, SXTC

*Chart delayed

Analyzing fundamentals for HUGE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see HUGE Fundamentals page.

Watching at HUGE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HUGE Technicals page.